#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Athero Review / 2018 - 2

The impact of rheumatic diseases on cardiovascular risk and lipidogram

Česká verzia

Authors: Vladimír Bláha
Authors place of work: III. interní gerontometabolická klinika LF UK a FN Hradec Králové
Published in the journal: AtheroRev 2018; 3(2): 126-132
Category: Reviews

Summary

Long-term mortality in rheumatic diseases is caused mainly by increased cardiovas­cular risk, which cannot be explained only by traditional risk factors. Rheumatic disease seems to be an independent  cardiovascular risk factor, which is influenced mainly by the type of therapy of rheumatic disease, blood lipid concentration and the magnitude of systemic inflammation. Moreover, lipid paradox plays a role, i.e. increased cardiovascular risk associates with lower total cholesterol, but low LDL-C does not mean reduced cardiovascular risk. To minimize cardiovascular risk of rheumatic patients the action for optimal control of the rheumatic disease activity, regular evaluation of cardio­vascular risk, screening for asymptoma­tic atherosclerosis and implementation of appropriate dietary, regime and therapeutical arrangements using hypolipidemic therapy, mainly by statins, is needed.

Key words:

atherosclerosis, cardiovascular disease, cardiovascular risk, hypercholesterolemia, LDL-cholesterol, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis

Zdroje
  1. Lindhardsen J, Ahlehoff O, Gislason GH et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide kohort study. Ann Rheum Dis 2011; 70(6): 929–934. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.143396>.
  2. Avina-Zubieta JA, Thomas J, Sadatsafavi M et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71(9): 1524–1529. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2011–200726>.
  3. Jürgen Braun, Klaus Krüger, Bernhard Manger et al. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int 2017; 114(12): 197–203. Dostupné z DOI: <http://dx.doi.org/10.3238/arztebl.2017.0197>.
  4. Krüger K. Therapie kardialer Risikofaktoren. Z Rheumatol 2016; 75(2): 173–182.
  5. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11(12): 693–704. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2015.112>.
  6. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17–28. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016–209775>.
  7. Chodara AM, Wattiaux A, Bartels CM. Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches. Curr Rheumatol Rep 2017; 19(4): 16. Dostupné z DOI: <http://dx.doi.org/10.1007/s11926–017–0643-y>.
  8. Crowson CS,Matteson EL, Roger VL et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012; 110(3): 420–424. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.03.044>.
  9. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336(7659): 1475–82. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.39609.449676.25>.
  10. Arts EE, Popa C, Den Broeder AA et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015;74(4):668–74. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–204024>.
  11. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094–1108. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60826–4>.
  12. Bukhari MA, Wiles NJ, Lunt M et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48(1): 46–53. Dostupné z DOI: <http://dx.doi.org/10.1002/art.10727>.
  13. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013; 72(12): 1897–1904. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–203485>.
  14. Kiadaliri AA, Felson DT, Neogi T et al. Brief report: rheumatoid arthritis as the underlying cause of death in thirty-one countries, 1987–2011: trend analysis of world health organization mortality database. Arthritis Rheumatol 2017; 69(8): 1560–1565. Dostupné z DOI: <http://dx.doi.org/10.1002/art.40091>.
  15. Myaseodova E, Matteson EL, Davis JM et al. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?. J Rheumatol 2017; 44(6): 732–739. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.161154>.
  16. Gwinnutt JM, Symmons DP, MacGregor AJ et al. Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Ann Rheum Dis 2018; 77(6): 848–854. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2017–212426>.
  17. Navarro-Millan I, Charles-Schoeman C, Yang S et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013; 65(6): 1430–1438. Dostupné z DOI: <http://dx.doi.org/10.1002/art.37916>.
  18. Winkleby MA, Feldman HA, Murray DM. Joint analysis of three U.S. community intervention trials for reduction of cardiovascular disease risk. J Clin Epidemiol 1997; 50(6): 645–658. Dostupné z DOI: <https://doi.org/10.1016/S0895–4356(97)00020–6>.
  19. Myasoedova E, Crowson CS, Kremers HM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70(3): 482–487. Dostupné z DOI: <https://doi.org/10.1136/ard.2010.135871>.
  20. Liao KP, Liu J, Lu B et al. Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non–Rheumatoid Arthritis Patients. Arthritis Rheumatol 2015; 67(8): 2004–2010. Dostupné z DOI: <https://doi.org/10.1002/art.39165>
  21. Plutzky J, Liao KP. Lipids in RA: Is Less Not Necessarily More? Curr Rheumatol Rep [online] 2018; 20(2): 8. <http://dx.doi.org/10.1007/s11926–018–0715–7>
  22. Myasoedova E, Crowson CS, Kremers HM et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69(7): 1310–1314. Dostupné z DOI: <https://doi.org/10.1136/ard.2009.122374>.
  23. Charles-Schoeman C, Fleischmann R, Davignon J et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015; 67(3): 616–625. Dostupné z DOI: <https://doi.org/10.1002/art.38974>.
  24. Robertson J, McInnes L, Porter D et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis 2017; 76(11): 1949–1952. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2017–211708>.
  25. Ormseth MJ, Yancey PG, Solus JF et al. Effect of drug therapy on net cholesterol efflux kapacity of high-density lipoprotein-enriched serum in rheumatoid arthritis. Arthritis Rheumatol 2016; 68(9): 2099–2105. Dostupné z DOI: <https://doi.org/10.1002/art.39675>.
  26. Rohatgi A, Khera A, Berry JD et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371(25): 2383–2393. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa1409065>.
  27. Ronda N, Greco D, Adorni MP et al. Newly identified antiatherosclerotic activity of methotrexat and adalimumab: complementary effects on lipoprotein afunction and macrophage cholesterol metabolism. Arthritis Rheumatol 2015; 67(5): 1155–1164. Dostupné z DOI: <https://doi.org/10.1002/art.39039>.
  28. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21) : 2195–2207. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0807646>.
  29. Ridker PM, Everett BM, Thuren T et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377(12): 1119–1131. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa1707914>.
  30. Solomon DH, Reed GW, Kremer JM et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015; 67(6): 1449–1455. Dostupné z DOI: <https://doi.org/10.1002/art.39098>.
  31. Kitas GD, Nightingale P, Armitage J et al. Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis [abstract 2126]. Arthritis Rheumatol 2015; 54(suppl 10): 87. Dostupné z DOI: <http://acrabstracts.org/abstract/trial-of-atorvastatin-for-the-primary-prevention-of-cardiovascular-events-in-patients-with-rheumatoid-arthritis>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Článek Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial
Článek Cardiovascular risk in patients with rheumatoid arthritis
Článek The effect of treatment of rheumatic diseases on cardiovascular risk
Článek The relationship of MicroRNA and osteoporosis when chronic heart failure is involved
Článek What a rheumatologist should know about statins and their side effects
Článek Detection of aortic calcifications within the assessment of lateral densitometric scans
Článek Familial chylomicronemia: pathogenesis, clinical manifestations and case study
Článek Nutritional intervention in a female patient with familial chylomicronemia: a case report
Článok vyšiel v časopise

Athero Review

Číslo 2
2018 Číslo 2
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#